AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026. Under the agreement, Apogee shareholders received $135.11 per share in cash for a total equity value of approximately $10.9 billion. The transaction adds late-stage assets zumilokibart (APG777) and APG273 to AbbVie's immunology pipeline targeting atopic dermatitis, asthma, and COPD. AbbVie expects the acquisition to dilute adjusted diluted EPS by $0.14 in 2026 and approximately $0.46 in 2027, with accretion beginning in 2032. The company reaffirmed its full-year 2026 adjusted diluted EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. AbbVie is a pharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics.

On August 18, 2026, AbbVie Inc. completed a $9.5 billion underwritten public offering of senior notes to fund its acquisition of Apogee Therapeutics, Inc. The issuance included $500 million in floating rate notes due 2028, $1 billion in 4.500% notes due 2028, $1.25 billion in 4.650% notes due 2030, $1.5 billion in 4.875% notes due 2031, $1.25 billion in 5.050% notes due 2033, $1.5 billion in 5.300% notes due 2036, $1 billion in 5.450% notes due 2038, $1.5 billion in 6.000% notes due 2056, and $500 million in 6.100% notes due 2066. Proceeds will primarily cover cash consideration for the Apogee acquisition and related expenses, with remaining funds allocated to general corporate purposes. The company operates in the biopharmaceutical industry.

On August 4, 2026, AbbVie Inc. entered into an underwriting agreement to issue and sell $9.5 billion in aggregate principal amount of senior notes across multiple maturities ranging from 2028 to 2066. The offering includes floating rate notes due 2028, fixed-rate notes due 2028, 2030, 2031, 2033, 2036, 2038, 2056, and 2066. Net proceeds are expected to be approximately $9.93 billion after deducting underwriting discounts and offering expenses. AbbVie intends to use these funds to finance a portion of its cash payment obligations for the acquisition of Apogee Therapeutics, Inc., pay related fees and expenses, and reduce commitments under its $10.0 billion 364-day delayed draw term loan facility associated with that transaction. The closing is expected on August 18, 2026. AbbVie operates in the pharmaceutical industry, developing and commercializing innovative medicines.

AbbVie Inc. reported second-quarter 2026 financial results with net revenues of $16.99 billion, a 10.2 percent increase, and adjusted diluted EPS of $3.65, up 22.9 percent. The company announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion to expand its immunology portfolio, with the transaction expected to close in the third quarter of 2026. AbbVie updated its full-year adjusted diluted EPS guidance range downward from $13.91-$14.11 to $13.87-$14.07, reflecting a $0.14 per share dilutive impact from the acquisition and $0.58 in acquired IPR&D expenses. Key product highlights included Skyrizi revenues of $5.5 billion and Rinvoq revenues of $2.5 billion. AbbVie Inc. operates in the pharmaceutical industry, discovering and delivering innovative medicines across immunology, neuroscience, oncology, and aesthetics.

AbbVie reported that second-quarter 2026 GAAP and adjusted non-GAAP earnings will include a pre-tax acquired IPR&D and milestones expense of $291 million, reducing diluted earnings per share by $0.17. Consequently, the company provided updated guidance for the second quarter of 2026 with an adjusted diluted EPS range of $3.57 to $3.61. The full-year 2026 adjusted diluted EPS guidance range, incorporating this expense, is now $13.91 to $14.11. AbbVie is a biopharmaceutical company that discovers, develops, and markets advanced therapies.

On June 22, 2026, AbbVie Inc. and Apogee Therapeutics, Inc. announced a definitive agreement for AbbVie to acquire Apogee. The transaction is expected to be accretive to AbbVie's adjusted diluted earnings per share beginning in 2032. The acquisition includes Apogee's pipeline assets, specifically zumilokibart (APG777) and APG273. AbbVie operates in the biopharmaceutical industry, developing and marketing advanced therapies for complex health conditions.